The increased expression of ITGB1 was also observed in other tumors, such as prostate cancer [34], ovarian carcinoma [35], lung cancer [36], colorectal adenocarcinomas [37], and in triple negative breast cancer [38]. Here, ITGB1 is linked to triple-negative breast carcinoma.